Ruptured Spleen in Factor XIII Deficiency

Total Page:16

File Type:pdf, Size:1020Kb

Ruptured Spleen in Factor XIII Deficiency Journal of Medical Genetics and Genomics Vol. 1(1), pp. 008-011, October, 2009 Available online at http://www.academicjournals.org/JMGG © 2009 Academic Journals Full Length Research Paper Ruptured spleen in factor XIII deficiency Kakil Ibrahim Rasul*, Mohamed Sadiq Ahmed and Abdul-Rahman Zar Gul Hamad Medical Corporation, Al-Amal Hospital, P.O. Box 3050, Doha, Qatar. Accepted 23 September, 2009 Factor XIII deficiency is a rare bleeding disorder, and spontaneous spleen rapture is not reported in cases of this disorder. We report 2 cases of spontaneous ruptured spleen in 2 young Pakistani boys who were known factor XIII deficiency who were presented at the same time within 24 h. Both cases were recovered and one was successfully treated conservatively while the other treated surgically by spleenectomy. It should also remind physicians that bleeding disorders may have unusual presentations and should keep in mind ruptured spleen in the differential diagnosis of patient with factor XIII deficiency presenting with acute abdomen. The treatment is either surgery or conservatively depending on the progress of the bleeding. Key words: Factor XIII deficiency, ruptured spleen, bleeding diathesis. INTODUCTION Congenital factor XIII (FXIII) deficiency is a rare autoso- plasma XIII is long, and low plasma levels are sufficient mal recessive disease usually associated with a severe for haemostasis (Anwar et al., 2002). bleeding diathesis. The incidence is about 1 case per 2 - 5 million populations. The male-to-female ratio is 1:1. FXIII is a plasma transglutaminase that catalyzes the final Case 1 step in the coagulation cascade, cross-linking the loose fibrin polymer into a highly organized structure. In A.S is a 19-year-old patient presented in May, 2007 to addition, FXIII covalently binds fibronectin, 2-plasmin in- A&E with severe abdominal pain, started all of a sudden hibitor, and other molecules to the fibrin plug; this en- at home when he was inside bathroom, the pain was hances adherence to the wound site, resistance to fi- agonizing, increasing in intensity, without history of neith- brinolysis, and wound healing. Deficiency of factor XIII er constipation nor diarrhea, involving the whole abdo- results in bleeding diasthesis. Physical manifestations men but mainly left hypochondia associated with difficulty related to bleeding may include the following: Persistent of breathing and the patient was anxious. Also, he repor- bleeding from the stump of the umbilical cord, soft tissue ted left side basal pleuritic chest pain. He was denying hi- bleeding, neurologic findings commensurate with central story of trauma. Urgent CT scan of the abdomen (Figure nervous system hemorrhage, bleeding in the oral cavity, 1) showed subcapsular splenic tear and hematoma with hemarthroses or periarticular bleeding, poor wound hea- intraabdominal collection, which was hemorrhagic. The ling The principal sites of bleeding are intracranial, um- patient was admitted to medical intensive care unit, bilical cord, superficial bruising and hematoma forma- managed conservatively by fresh frozen plas-ma (FFP) tion, oral cavity (Ernest Beutler et al.,1994). Diagnosis is and tranexamic acid. No surgical intervention done. CT made by normal coagulation screening tests and a de- angio showed no bleeding but capillary blee-ding which is tailed family history. Specific factor XIII assays can not feasible for arterial embolization. The patient received confirm the diagnosis. The condition can also be defined 10 - 20 ml/kg FFP q12H for first 5 days and also he was by a clot solubility test. Because of the severity of the transfused 5 units PRBC. After five days from his bleeding diathesis, prophylaxis is desirable and has been admission, his hemoglobin became stable around 10 shown to be very effective as the in vivo half-life of g/dL, FFP stopped and maintained on ferrous sulfate treatment, because of shortness of breath and ta- chypnea and chest pain, he was kept on IV Tazobactam and Piperacillin (Tazocin) on assumption of chest infec- *Corresponding author. E-mail [email protected]. Fax +974 tion by chest x-ray. Five days later, he had oxygen 4397857 desaturation for which spiral CT chest showed suspicious Rasul et al. 009 Figure 1. Case number 1, CT scan abdomen for case number 1 showing the ruptured spleen. small pulmonary embolism in one of the left basal pulmo- the large joints like elbows, hips, and knees. In one nary arteriole. But the patient was not started on any admission in 2005, he had intra-abdominal bleeding with treatment especially he was feeling much better, without abdominal hematoma and one of other severe episodes; pain, and no more shortness of breath. he had huge hemiarthrosis of the knee joint. During all He had been diagnosed as factor XIII deficiency, pre- these episodes, he was managed by fresh frozen plasma sented at 1-month-old with hematoma post vaccination 10 - 20 ml/kg /day for two to three days in addition to IV and with later post circumcision bleeding then followed at or oral tranexamic acid 1 gm 8 hourly and given ferrous Pediatric Hematology out patient department for frequent sulfate for his constantly low hemoglobin 100 - 120 g/L. intra-articular and paraarticular soft tissue bleeding even After the incident of knee joint hemiarthrosis early 2006 after trivial trauma. Then after the age of 14, his care and at age of 18 years old, the patient was started on transferred to us as Adult Hematology Team. The patient fresh frozen plasma prophylaxis 5 ml/kg every two to continued to have same type of bleeding mainly involving three weeks and for about one year, his condition was 010 J. Med. Genet. Genomics Figure 2. CT scan of abdomen for case number 2, showing the ruptured spleen. very well without bleeding. His hemoglobin was trending Case 2 to be more than 120 g/L but over the last two months, he stopped receiving FFP prophylaxis. F.M.B a 17 years old Pakistani male patient had been di- agnosed as factor XIII deficiency at age of 2 years when Social history: Nonsmoker nonalcoholic low to medium he developed bleeding after circumcision, he had history social class. Finished his secondary school two years of repeated hematomas in the thigh, lips and bleeding ago and he is not employed. Not athletic. after tooth extraction, presented on 3rd of June, 2007 pre- sented to the emergency department with sudden onset Family history: The patient’s father has no chronic severe abdominal pain of few hours duration, an urgent illness. No bleeding tendencies. The mother has no CT scan of the abdomen (Figure 2) revealed raptured sp- bleeding tendency but history of migraine and convulsing leen, patient received 2 unit PRBC and 5 units of FFP disorder. The patient has two little brothers. The youngest and underwent splenectomy, continued FFP after surgery has factor XIII deficiency and the other has no bleeding until stablised. Post operatively patient developed short- tendency so far and three sisters one older than the ness of breath and fever CXR showed bilateral infiltration, patient and 2 younger, none had bleeding tendency and patient started on antibiotic and had smooth recovery. screening test for factor XIII deficiency were negative. In family history, his parents are first degree cousin he Rasul et al. 011 had 2 sisters one of them diagnosed factor XIII deficiency REFERENCES and he had 3 brothers one died at age of 6 years from *Ernest B, Marshall L, Barry C, Thomas Ki, (1994). Hereditary and unknown reason. acquired deficiencies of activated factor XIII – William’s Hematology, 5th ed. McGraw Hill Inc. New York, 5th ed. pp. 1455-1457. Anwar R, Minford A, Gallivan L, Trinh CH, Markham AF (2002). Delayed DISCUSSION umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 109. Waks D, Arnout J, Demulder A, Ferster A, Fondu P (1989). Inherited Factor XIII (FXIII) deficiency is a rare inherited disease factor XIII deficiency, Acta Clin. Belg. 44 (1):52-57. usually associated with a severe bleeding diathesis, with Anwar R, Miloszewski KJ. Br J Haematol. (1999). Factor XIII deficiency. very low incidence which is about 1 case per 2 - 5 million Br J. Haematol. 107: 468–84. Shaikh AN, Khurshid M.(1993) Apr J Pak Med Assoc. ; 43 (4):67-9. populations and equal incidence in both male in female. Board PG, Losowsky MS, Miloszewski KJ (1993 Dec), Factor XIII: Signs of bleeding include the following: CNS hemorrhage inherited and acquired deficiency. Blood Rev. 7 (4): 229-242. is frequent (25 - 30%) and may occur spontaneously or after minor trauma. Prevention of this complication is the major rationale for initiating prophylactic therapy. Infants are at risk of bleeding immediately after birth; the greatest risk is due to CNS hemorrhage. Soft tissue bleeding and bruising are very common, as is bleeding into the mouth and gums during teething. Hemarthroses occur in 20% of cases; however, incidence is less frequent than in severe hemophilia. Bleeding that is delayed (that is 12 - 36 h) after trauma or surgery is pathognomonic of FXIII de- ficiency. Recurrent spontaneous abortions are very common in women with FXIII deficiencies who do not receive FXIII replacement. Wound healing is abnormal in a small number of patients; therefore, FXIII may have a role in tissue repair (Waks et al., 1989; Anwar et al., 1999; Shaikh and Khurshid, 1993). We report 2 cases presented with spontaneously ruptured spleen in 2 young male Pakistani patients with in 24 h. There is high inci- dence of consanguinity was observed in affected families of factor XIII deficiency among Pakistanis (Board et al., 1993). It know that rupture of solid organ as liver , spleen kidney can occur after trauma but in a search of the Medline the occurrence of spontaneous rapture of spleen is not reported in the literatures.
Recommended publications
  • Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism
    International Journal of Molecular Sciences Review Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism Michał Z ˛abczyk 1,2 , Joanna Natorska 1,2 and Anetta Undas 1,2,* 1 John Paul II Hospital, 31-202 Kraków, Poland; [email protected] (M.Z.); [email protected] (J.N.) 2 Institute of Cardiology, Jagiellonian University Medical College, 31-202 Kraków, Poland * Correspondence: [email protected]; Tel.: +48-12-614-30-04; Fax: +48-12-614-21-20 Abstract: Coagulation factor XIII (FXIII) is converted by thrombin into its active form, FXIIIa, which crosslinks fibrin fibers, rendering clots more stable and resistant to degradation. FXIII affects fibrin clot structure and function leading to a more prothrombotic phenotype with denser networks, characterizing patients at risk of venous thromboembolism (VTE). Mechanisms regulating FXIII activation and its impact on fibrin structure in patients with acute VTE encompassing pulmonary embolism (PE) or deep vein thrombosis (DVT) are poorly elucidated. Reduced circulating FXIII levels in acute PE were reported over 20 years ago. Similar observations indicating decreased FXIII plasma activity and antigen levels have been made in acute PE and DVT with their subsequent increase after several weeks since the index event. Plasma fibrin clot proteome analysis confirms that clot-bound FXIII amounts associated with plasma FXIII activity are decreased in acute VTE. Reduced FXIII activity has been associated with impaired clot permeability and hypofibrinolysis in acute PE. The current review presents available studies on the role of FXIII in the modulation of fibrin clot properties during acute PE or DVT and following these events.
    [Show full text]
  • Factor XIII Deficiency
    Factor XIII deficiency Information for families Great Ormond Street Hospital for Children NHS Foundation Trust 2 Factor XIII deficiency is a type of clotting disorder. A specific protein is missing from the blood so that injured blood vessels cannot heal in the usual way. This information sheet from Great Ormond Street Hospital (GOSH) explains the causes, symptoms and treatment of Factor XIII deficiency and where to get help. What is a clotting disorder? A clotting (or coagulation) disorder is a on in order. When all of the factors are turned medical condition where a specific protein on, the blood forms a clot which stops the is missing from the blood. injury site bleeding any further. Blood is made up of different types of There are a number of coagulation factors cells (red blood cells, white blood cells and circulating in the blood, lying in wait to be platelets) all suspended in a straw-coloured turned on when an injury occurs. If any one liquid called plasma. Platelets are the cells of the factors is missing from the body, the responsible for making blood clot. When complicated chemical reaction described a blood vessel is injured, platelets clump above will not happen as it should. This can together to block the injury site. They also lead to blood loss, which can be severe and start off a complicated chemical reaction to life-threatening. Each coagulation factor form a mesh made of a substance called fibrin. is given a number from I to XIII – they are This complicated chemical reaction always always written as Roman numerals – and follows a strict pattern – with each clotting the effects of the missing factor will vary.
    [Show full text]
  • The Rare Coagulation Disorders
    Treatment OF HEMOPHILIA April 2006 · No. 39 THE RARE COAGULATION DISORDERS Paula HB Bolton-Maggs Department of Haematology Manchester Royal Infirmary Manchester, United Kingdom Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2006 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s web site at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Autosomal Recessive Inherited Bleeding Disorders in Pakistan
    Naz et al. Orphanet Journal of Rare Diseases (2017) 12:66 DOI 10.1186/s13023-017-0620-6 RESEARCH Open Access Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions Arshi Naz1* , Muhammad Younus Jamal1, Samina Amanat2, Ikram Din ujjan3, Akber Najmuddin4, Humayun Patel1, Fazle Raziq5, Nisar Ahmed6, Ayisha Imran7 and Tahir Sultan Shamsi1 Abstract Background: Autosomal recessive bleeding disorders (ARBDs) include deficiencies of clotting factors I, II, V, VII, X, XI, XIII, vitamin K dependent clotting factors, combined factor V & VIII, Von Willebrand Disease (vWD) type 3, Glanzmann’s thrombasthenia (GT) and Bernard–Soulier syndrome. Patients with primary bleeding disorders from all the major provincial capitals of Pakistan were screened for ARBDs. Prothrombin (PT), activated partial thromboplastin time (APTT), bleeding time (BT) and fibrinogen levels were measured. Cases with isolated prolonged APTT were tested for factors VIII and IX using factor assays This was followed by FXI:C level assessment in cases with normal FVIII and FIX levels. vWD was screened in patients with low FVIII levels. Factors II, V and X were tested in patients with simultaneous prolongation of PT and APTT. Peripheral blood film examination and platelet aggregation studies were performed to assess platelet disorders. Urea clot solubility testing was done to detect Factor XIII levels where platelet function tests were normal. Descriptive analysis was done using SPSS version 16. Results: Of the 429 suspected bleeding disorder patients, 148 (35%) were diagnosed with hemophilia A and 211 (49.1%) patients had ARBDs. 70 patients (16.3%) remained undiagnosed. Out of 211 patients with ARBD; 95 (33.8%) had vWD type 3.
    [Show full text]
  • Factor XIII Deficiency
    FACTSHEET Factor XIII deficiency This factsheet is about a bleeding disorder parents. It affects men and women equally. that is related to problems with a blood clotting factor called factor XIII (pronounced If you carry one copy of the gene fault for factor 13). It is written to go with our Rare factor XIII deficiency, you are known as a bleeding disorders booklet, where you will carrier. You can only pass the condition on to find much more information on living with your children if your partner also carries the one of these conditions. gene fault. You will not have the condition yourself, but any children that inherit the What is factor XIII deficiency? gene fault from you will also be carriers of the condition. Factor XIII deficiency is a bleeding disorder caused by the body producing less of a It is also possible to develop factor XIII clotting factor than it should. This causes deficiency later in life. This is called acquired problems because the clotting reaction factor XIII deficiency. It can be caused by that would normally control any bleeding liver disease, some types of leukaemia, is blocked too early. So your body doesn’t inflammatory bowel disease and an auto- make the blood clots it needs to stop immune disease called systemic lupus bleeding. erythematosus. Factor XIII deficiency is one of the rarest Symptoms of factor XIII deficiency types of clotting disorder. Doctors estimate that it affects about one in every two million Often, the first clinical sign of inherited people. Factor XIII plays an important role in factor XIII deficiency is a few days after wound healing, pregnancy and formation of birth or when the umbilical cord separates.
    [Show full text]
  • Blood Coagulation Overview and Inherited Hemorrhagic Disorders 2002 Abshire
    Blood Coagulation Overview and Inherited Hemorrhagic Disorders 2002 Abshire 1) Thrombin is one of the key proteins in the coagulation cascade and has both procoagulant and anticoagulant properties. Which one of the following is an important anticoagulation function: a. Activation of factors V and VIII b. Factor XIII activation c. Stimulation of the thrombin activated fibrinolytic inhibitor (TAFI) d. Complex with thrombomodulin (TM). 2) The endothelial cell lining blood vessels possesses several important anticoagulation functions . Which one of the following is one of its' important hemostasis (procoagulant) functions? a. Production of nitric oxide (NO) b. Activation of thrombomodulin (TM) c. Release of plasminogen activator inhibitor (PAI-I) d. Release of TPA e. Interaction of heparin sulfate with anti-thrombin III (AT III) 3) A term well infant is born without complications after a normal pregnancy and initial nursery stay. Upon drawing the metabolic screen, the baby is noted to have prolonged oozing from the heelstick sample. CBC, plt ct, PT, a PTT and fibrinogen were normal. Family history is negative. He returns for the 2 week check and the mother notices that the umbilical cord has been oozing for 4 days. A screening test for factor XIII deficiency is ordered and the baby's clot does not dissolve in 5 M urea. The euglobulin lysis time (ELT) was less than one hour. The most likely diagnosis is: a. Factor XIII heterozygous deficiency b. Homozygous antiplasmin deficiency c. Mild hemophilia B (Factor IX deficiency) d. von Willebrand Disease e. Tissue plasminogen activator (TPA) excess. 4) The newborn's coagulation system is both similar and quite different from a child's.
    [Show full text]
  • Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis
    International Journal of Molecular Sciences Review Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis Vassilios P. Memtsas 1, Deepa R. J. Arachchillage 2,3,4 and Diana A. Gorog 1,5,6,* 1 Cardiology Department, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire SG1 4AB, UK; [email protected] 2 Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London SW7 2AZ, UK; [email protected] 3 Department of Haematology, Imperial College Healthcare NHS Trust, London W2 1NY, UK 4 Department of Haematology, Royal Brompton Hospital, London SW3 6NP, UK 5 School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, Hertfordshire AL10 9AB, UK 6 Faculty of Medicine, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK * Correspondence: [email protected]; Tel.: +44-207-0348841 Abstract: Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this review article, we discuss the (patho)physiological role and laboratory assessment of fibrin, factor XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in Citation: Memtsas, V.P.; various disease states and assessment of cardiovascular risk. Arachchillage, D.R.J.; Gorog, D.A. Role, Laboratory Assessment and Keywords: factor XIII; fibrin; endogenous fibrinolysis; thrombosis; coagulation Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
    [Show full text]
  • Factor XIII Deficiency Diagnosis: Challenges and Tools
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by AIR Universita degli studi di Milano Received: 17 May 2017 | Accepted: 6 September 2017 DOI: 10.1111/ijlh.12756 REVIEW ARTICLE Factor XIII deficiency diagnosis: Challenges and tools M. Karimi1,2 | F. Peyvandi3 | M. Naderi4 | A. Shapiro2 1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Abstract 2Indiana Hemophilia & Thrombosis Center, Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from het- Indianapolis, IN, USA erogeneous mutations, which can lead to life- threatening hemorrhage. The diagnosis 3Angelo Bianchi Bonomi Hemophilia and of FXIIID is challenging due to normal standard coagulation assays requiring specific Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, FXIII assays for diagnosis, which is especially difficult in developing countries. This Italy report presents an overview of FXIIID diagnosis and laboratory methods and suggests 4Department Of Pediatrics Hematology and Oncology, Ali Ebn-e Abitaleb Hospital an algorithm to improve diagnostic efficiency and prevent missed or delayed FXIIID Research Centre for Children and Adolescents diagnosis. Assays measuring FXIII activity: The currently available assays utilized to Health [RCCAH], Zahedan University Of Medical Sciences, Zahedan, Iran diagnose FXIIID, including an overview of their complexity, reliability, sensitivity, and specificity, as well as mutational analysis are reviewed. The use of a FXIII inhibitor Correspondence Mehran Karimi, Hematology Research assay is described. Diagnostic tools in FXIIID: Many laboratories are not equipped with Center, Shiraz University of Medical Sciences, quantitative FXIII activity assays, and if available, limitations in lower activity ranges Nemazee Hospital, Shiraz, Iran.
    [Show full text]
  • Lessons Learned
    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
    [Show full text]
  • Coagulopathies Evangelina Berrios- Colon, Pharmd, MPH, BCPS, CACP • Julie Anne Billedo, Pharmd, BCACP
    CHAPTER33 Coagulopathies Evangelina Berrios- Colon, PharmD, MPH, BCPS, CACP • Julie Anne Billedo, PharmD, BCACP Coagulopathies include hemorrhage, thrombosis, and Activated protein C ( APC) inhibition is catalyzed by protein embolism, and represent common clinical manifestations of S, another vitamin K–dependent plasma protein, and also hematological disease. Normally, bleeding is controlled by requires the presence of platelet phospholipid and calcium. a fi brin clot formation, which results from the interaction Antithrombin III (AT III) primarily inhibits the activity of of platelets, plasma proteins, and the vessel wall. The fi brin thrombin and Factor X by binding to the factors and block- clot is ultimately dissolved through fi brinolysis. A derange- ing their activity. This inhibition is greatly enhanced by hep- ment of any of these components may result in a bleeding arin. Loss of function and/or decreased concentrations of or thrombotic disorder. In this chapter, individual disease these proteins result in uninhibited coagulation and hence a states are examined under the broad headings of coagulation predisposition to spontaneous thrombosis otherwise known factor defi ciencies, disorders of platelets, mixed disorders, as a hypercoagulable state. acquired thrombophilias, and inherited thrombophilias. Fibrinolysis is a mechanism for dissolving fi brin clots. Plasmin, the activated form of plasminogen, cleaves fi brin to produce soluble fragments. Fibrinolytics, such as tissue n ANATOMY, PHYSIOLOGY, AND PATHOLOGY plasminogen activator, streptokinase, and urokinase, acti- vate plasminogen, resulting in dissolution of a fi brin clot. Coagulation is initiated after blood vessels are damaged, enabling the interaction of blood with tissue factor, a pro- n CLASSES OF BLEEDING DISORDERS tein present beneath the endothelium ( Figure 33.1).
    [Show full text]
  • Glanzmann's Thrombasthenia: Working Through Cultural Barriers
    J Haem Pract 2016 3(2). doi:10.17225/jhp00088 CASE STUDY Glanzmann’s thrombasthenia: Working through cultural barriers Colleen Tapia, Maria Tovar-Herrera Glanzmann’s thrombasthenia is a rare autosomal recessive bleeding syndrome characterised by a lack of platelet aggregation. This case study considers a young woman affected by this disease, integrating the role her culture plays in her medical management. Fatima (patient renamed for the purposes of this case study) is a 16-year-old girl with Glanzmann’s thrombasthenia and heterozygous factor XIII deficiency, complicated by menorrhagia and a history of packed red blood cell (PRBC) transfusion for symptomatic anemia, with subsequent development of red blood cell (RBC) antibodies. Management has included years of working on hormone control, as well as dealing with the side-effects of such treatment, and starting NovoSeven (Novo Nordisk) recombinant factor VII infusions along with factor XIII replacement (Corifact; CSL Behring) via the use of a peripherally inserted central catheter (PICC), following set-backs related to hormone control. Glanzmann’s thrombasthenia had its first true ©Shutterstock Inc. impact on Fatima at the onset of her menstrual cycle, just prior to the start of her teenage years. Her first menstrual aggregation [1]. Mucocutaneous bleeding with absent cycle resulted in her admission to the intensive care unit platelet aggregation, in the presence of a normal platelet (ICU), where emergency measures were required to save count is diagnostic for this condition [1]. Treatment is usually her life. When options to help Fatima began to diminish, through platelet transfusion, however the severe onset of Corifact was initiated to correct her factor XIII deficiency, menorrhagia for women is a frequent clinical problem and thus allowing the cross-linking of fibrin to form a more is treated with high doses of progesterone [1].
    [Show full text]
  • Neonatal Hematology
    Neonatal Hematology Tung Wynn, MD April 28, 2016 Disclosures • I am site principal investigator for Baxalta, Novonordisk, Bayer, and AstraZeneca studies Hemophilia Factor VIII Def Protein C Def Factor IX Def Protein S Def Rare factor deficiencies Antithrombin III Def Factor XIII Factor V Leiden Mut Factor VII Prothrombin Mut Von Willebrands AntiPhospholipids Antibodies Thrombocytopenia Hyperhomocysteinemia Platelet dysfunctions MTHFR mutations Liver Disease Factor VIII elevation Vitamin K deficiency Liver Disease Afibrinogenemia Vitamin K deficiency Dysfibrinogenemia Dysfibrinogenemia Alpha-2 antiplasmin Def Plasminogen activator inhibitor-1 mut Plasminogen activator Inhibitor-1 Def Coagulation Anti-Coagulation Overview • Three phases of Coagulation – Vascular phase – Platelet phase • Platelet adhesion • Platelet aggregation – Coagulation phase • Intrinsic pathway • Extrinsic pathway • Clot contraction • Activation of coagulation also initiates the process of fibrinolysis Neonatal Hemostatic System Differences Coagulation Anticoagulation – Factor II – Plasminogen – Factor VII – Antithrombin III – Factor IX – Protein C – Factor X – Protein S – Factor XI – Factor XIII – Platelet levels are normal, but have wider variability Physiologic “deficiencies” of both coagulation and anticoagulation “balance” each other out in the neonate. General Approach to Neonatal bleeding • History – Fever – PPROM – Chorioamnonitis – Fetal Distress – Birth Trauma – Maternal infection – Maternal CBC – Family history autoimmune disease, coagulation disorder, low
    [Show full text]